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PENILAIAN HASIL RAWATAN TUBERKULOSIS, FAKTOR YANG 
MEMPENGARUHI PESAKIT YANG TIDAK MENGIKUTI  RAWATAN 
SUSULAN (DEFAULTERS) DAN KUALITI KEHIDUPAN BERKAITAN 
KESIHATAN DI YAMAN 
 
ABSTRAK 
Meskipun rawatan tuberkulosis (TB) didapati berkesan, TB masih merupakan 
cabaran penyakit berjangkit utama di seluruh dunia akibat peningkatan mortaliti dan 
morbiditi. Tambahan pula di Yemen, TB berada di tangga keempat penyebab 
kematian. Kajian terkini direka bagi menilai TB tpalitan smear positif kalangan 
pesakit smear positive pulmonary tuberculosis (PTB) termasuklah hasil rawatan, 
kualiti kehidupan berkaitan kesihatan (HRQoL) dan faktor risiko ke atas pesakit TB 
yang tidak mengikuti rawatan susulan. Satu kajian pengamatan prospektif direka. 
Kajian dijalankan ke atas dua bandar dengan penyebaran tinggi TB iaitu Taiz dan Al 
Hudaydah di Yemen antara April 2014 dan Januari 2016 yang memperoleh nilai 
kejayaan yang rendah iaitu 83%. Kajian mendapati bahawa lelaki (nisbah ods terlaras 
(AOR: 0.248, 95% CI: 0.239–0.874), buta huruf (AOR: 2.294, 95% CI: 1.272–
4.137), dan komorbiditi (AOR: 1.995, 95% CI: 1.108–3.590) merupakan faktor risiko 
berkaitan hasil yang tidak berjaya. Tambahan pula, mereka yang tinggal di kawasan 
pendalaman (AOR: 1.97, 95% CI: 1.280-2.919), mempunyai BMI ≥ 18.5 kg/m2 
(AOR: 2.85, 95% CI: 2.194-3.652) adalah faktor risiko berkaitan fasa intensif semasa 
tempoh penukaran sputum. Penduduk yang tinggal di kawasan pendalaman (nisbah 
ods terlaras) (AOR: 2.358, 95% CI: 0.658–4.00), mengunyah daun khat (AOR: 
2.615, 95% CI: 1.201–5.691), batuk selama >3 minggu pada awal rawatan (AOR: 
xvi 
 
2.672, 95% CI: 1.053–6.782), dan luka dua hala semasa radiografi (AOR: 2.134, 95% 
CI: 1.147–3.972) merupakan faktor risiko berkaitan tempoh rawatan pelanjutan. 
Kualiti kehidupan berkaitan kesihatan (HRQoL) dalam kalangan pesakit TB dan 
semua pesakit baru yang mendaftar sebagai pesakit TB diminta melengkapkan 
sendiri soal selidik SF-36 pada awal rawatan, akhir fasa intensif (I.P) dan akhir fasa 
lanjutan (C.P). Pada akhir rawatan, skor komponen fizikal tinggi (PCS) (48.9) 
diperoleh sebagai perbandingan dengan skor komponen mental (MCS) (44.3) yang 
menunjukkan tekanan mental tinggi disebabkan aspek emosi. Oleh yang demikian, 
peramal perbezaan dalam min MCS yang tinggal di bandar Al Hudaydah, 
mengunyah daun khat, stigmatisasi dan tempoh rawatan lebih daripada 6 bulan. 
Kajian mendapati bahawa nilai pesakit yang tidak mengikuti rawatan susulan adalah 
12.6% (52 pesakit). Pesakit berasal daripada kawasan pendalaman (nisbah ODS 
terlaras (AOR: 3.343, 95% CI: 1.362–8.208), buta huruf (nisbah ods terlaras (AOR: 
13.362, 95% CI: 4.231–42.197), mempunyai tabiat merokok, (nisbah ods terlaras 
(AOR: 12.047, 95% CI: 4.307–33.696), stigmatisasi (nisbah ods terlaras (AOR: 
3.365, 95% CI: 1.561–9.573), rendah BMI (nisbah ods terlaras (AOR: 4.016, 95% 
CI: 1.620–9.954), kos perjalanan tinggi (nisbah ods terlaras (AOR: 14.190, 95% CI: 
4.560–44.156), dan kesan sampingan (nisbah ods terlaras (AOR: 2.780, 95% CI: 
1.092–7.077) adalah seperti faktor risiko berkaitan dengan pesakit yang tidak 
mengikuti rawatan susulan. Tambahan lagi, dalam kalangan 52 pesakit, 32 pesakit 
dilkuti untuk mengenal pasti sebab mereka meninggalkan rawatan susulan. Kos 
perjalanan tinggi (48.1%), kesan sampingan (32.7 %) dan stigmatisasi (30.8 %) 
merupakan sebab utama mereka tidak mengikuti rawatan dan diikuti dengan 
penambahbaikan dari aspek kesihatan (19.2 %), kos perubatan (15.4 %), tidak hadir 
bekerja semasa rawatan (13.5 %), jarak yang jauh untuk ke pusat TB (11.5 %), dan 
xvii 
 
ketidakpuasan hati dengan perkhidmatan kesiahatan (11.5 %). Oleh itu, mengambil 
kira faktor risiko pesakit yang tidak mengikuti rawatan susulan dan sebab utama 
mereka meninggalkan rawatan susulan boleh membantu mengurangkan kadar pesakit 
meninggalkan rawatan susulan dan meningkatkan hasil rawatan. HRQol bagi pesakit 
yang tidak menjalani rawatan susulan dilaporkan mempunyai skor MCS yang rendah 
iaitu 28.9 yang menandakan keadwan yang kurang memuaskan dan tinggi risiko 
untuk depresi. Oleh itu, skor MCS yang rendah boleh diguna pakai oleh pekerja 
pasukan TB untuk menjangkan pesakit yang mungkin tidak menjalani rawatan 
susulan di masa hadapan. 
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EVALUATION OF TREATMENT OUTCOMES, FACTORS AFFECTING 
TREATMENT DEFAULTING AND HEALTH RELATED QUALITY OF 
LIFE OF NEWLY DIAGNOSED TUBERCULOSIS PATIENTS IN YEMEN 
ABSTRACT 
Despite the effectiveness of tuberculosis (TB) treatment, TB remains the most 
challenging infectious disease worldwide due to augmented trend of mortality and 
morbidity. In addition, in Yemen, TB consider as the 4
th
 causes of death. Present
study is designed to evaluates TB among smear positive pulmonary tuberculosis 
(PTB) including treatment outcome, health related quality of life (HRQoL) and risk 
factors associated with TB defaulters. A prospective cohort study was designed. The 
study conducted in two high TB prevalent cities (Taiz and Al Hudaydah) of Yemen, 
between April 2014 and January 2016. Moreover, this study reported a lower success 
rate of 83% compare to WHO target of 85%.  Likewise, the study report male gender 
(adjusted odds ratio [AOR]: 0.248, 95% CI: 0.239–0.874), illiterate (AOR: 2.294, 
95% CI: 1.272–4.137), and comorbidity (AOR: 1.995, 95% CI: 1.108–3.590) were the 
risk factors associated with unsuccessful outcome.  Moreover, living in rural areas 
(AOR: 1.97, 95% CI: 1.280-2.919),, having BMI ≥ 18.5 kg/m2 (AOR: 2.85, 95% CI: 
2.194-3.652) were the risk factors related to prolonging sputum conversion during 
intensive phase. Moreover living in a rural area (adjusted odds ratio [AOR]: 2.358, 
95% CI: 0.658–4.00), smoking (AOR: 0.054, 95% CI: 0.987–4.112),  chewing khat 
(AOR: 2.615, 95% CI: 1.201–5.691), having a cough for >3 weeks at the start of 
treatment (AOR: 2.672, 95% CI: 1.053–6.782), and bilateral lesions during 
radiography (AOR: 2.134, 95% CI: 1.147–3.972)  were a risk factor related to 
xix 
 
prolonging treatment duration (> 6 months). Health related quality of life (HRQoL) 
among TB patients, all newly registered TB patients ask for the self-complete SF-
36V2 survey at the beginning of treatment, end of the intensive phase (I.P) and end 
of the continuous phase (C.P). At the end of the treatment, a higher physical 
component score (PCS) (48.9) obtained as compared to mental component score 
(MCS) (44.3) showing higher mental distress due to emotional aspects. Likewise, the 
predictors of difference in mean MCS were living in Al Hudaydah city, chewing 
khat, stigmatization and treatment duration more than 6 months. This study reported 
defaulter rate of 12.6% (52 defaulters). The patients coming from rural areas (AOR: 
3.343, 95% CI: 1.362–8.208), illiteracy (AOR: 13.362, 95% CI: 4.231–42.197),, 
having a smoking habit (AOR: 12.047, 95% CI: 4.307–33.696),, stigmatization 
(AOR: 3.365, 95% CI: 1.561–9.573), low BMI (AOR: 4.016, 95% CI: 1.620–9.954),, 
high travel cost (AOR: 14.190, 95% CI: 4.560–44.156), and side effects (AOR: 
2.780, 95% CI: 1.092–7.077)  reported as a risk factor associated with defaulters. 
Moreover, among 52 defaulters, 32 were followed to identify the reasons of default. 
High travel cost (48.1 %), side effect (32.7 %), and stigmatization (30.8 %) were the 
main reasons for defaulting, followed by improved health condition (19.2 %), 
medication cost (15.4 %  ( , Missed work during treatment period (13.5 %), far 
distance to TB centres ) 11.5 %  ( , and dissatisfaction with health services (11.5 %). 
Considering defaulting risk factors and the main reasons for defaulting may help to 
reduce future defaulter rates and improve the treatment outcomes.  HRQoL of TB 
defaulters reported a low MCS score of 28.9 to indicate the poor condition and a 
higher risk of depression Thus; low MCS can assist TB workers to predict future TB 
treatment defaulters. 
 1 
 
1 CHAPTR ONE: INTRODUCTION 
INTRODUCTION 
1.1 General Introduction  
This chapter comprises a brief overview of treatment outcomes and health-
related quality of life (HRQoL) of tuberculosis (TB) patients in addition to causes of 
patients‟ defaulting from treatment. TB as a global phenomenon is also explained. In 
addition, the epidemiology, management and treatment of TB in Yemen and follow 
up drug treatment are discussed. This chapter also presents the problem statement, 
rationale and importance of the study, research contribution, aim and objectives. 
1.2 Tuberculosis as a global phenomenon 
TB is an infectious disease caused by an organism called Mycobacterium 
tuberculosis (tubercle bacilli). Despite an increase success rate against TB 
worldwide, it remains a globally serious problem. World Health Organization (WHO) 
estimates that over 30% of the world population is infected with either dormant or 
active tuberculosis (TB) (WHO, 2014). TB is a deadly disease that results in an 
estimated 1.5 million deaths annually (Sharpe et al., 2016). In addition, any organ in 
the human body can be affected by TB, but the most infected organ is the lung. The 
case of lung infected with TB is referred to as pulmonary tuberculosis (PTB), while 
extrapulmonary tuberculosis (EPTB) is for cases where other organs are affected. 
PTB is spread very fast by small droplets (containing bacillus) from a cough or 
sneeze of an infected patient. However, TB only advances into a disease in low 
proportions of infected persons (WHO, 2011). .  
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1.3 Epidemiology of Tuberculosis    
1.3.1 Global epidemiology of Tuberculosis  
In 2015, approximately 10 million people are infected with TB (of which 
60% are considered new), in addition to 1.5 million deaths  annually (Muliaditan et 
al., 2016); (Hochberg et al., 2016); (WHO, 2015). Furthermore, approximately 94% 
of overall TB cases and over 95% of death cases occurred in low-income nations 
(Bøhler, Mustafaa and Mørkve, 2005). Apart from the 60% reported cases, others are 
considered undiagnosed or not reported to national TB control programs (NTP). 
Similarly, studies reported that approximately 70% of TB cases infected with sputum 
smear-positive pulmonary TB died within 10 years (WHO, 2015). An estimated 13 
% of newly TB cases were diagnsod as HIV-infected, which is considered high, with 
the majority of cases reported in developing countries. Furthermore, TB was reported 
to have declined in industrial countries, but remains prevalent in poor and developing 
countries (Norheim et al., 2015). India is considered the country with the highest 
number of TB cases followed by China with a global rate of 24% and 11%, 
respectively (WHO, 2014). The number of TB cases declined globally to an average 
of 1.5 % per year between 2000 and 2013 (WHO, 2014). In 2014, WHO reported 
half million more cases of TB compared to 2013 (WHO, 2014). An estimated 95% of 
total world TB cases and 98% of the mortality due to TB are reported in developing 
countries, with 75% among the productive age group (15-50 years old) (WHO, 
2010). The most recent WHO reports show that approximately 56% of global TB 
cases are in south-east Asian and western Pacific regions (WHO, 2016). African 
region comprises 25% of world TB cases and highest mortality rate. 
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Tuberculosis (TB) ranks globally as the second foremost cause of mortality 
among infectious diseases after HIV (WHO, 2013b). TB is directly associated with 
overpopulation and poverty. It also co-related to other diseases and addictive 
behaviours such as smoking, HIV and diabetes (Perrin, 2015). WHO estimates that 
the number of TB cases in 2020 will reach 1 billion. Among them, approximately 35 
million will succumb to the disease if TB control is not strengthened globally (WHO, 
2005). Legesse et al., (2010) reported that the key factors associated with increased 
risk of TB is poverty and lack of awareness. Several factors play a significant role in 
controlling TB such as adequate knowledge and awareness, and appropriate 
treatment. 
1.3.2 Epidemiology of Tuberculosis in Yemen  
Yemen is an Arabian country with 26 million population (WHO, 2015). 
Yemen is situated in WHO‟s Eastern Mediterranean Region (EMR) and rank as an 
intermediate TB-burdened country (WHO, 2013b). The countries in the EMR are 
categorized into three distinct epidemiological categories. The first group entails 
countries with an estimated incidence of 50 or more tuberculosis patients (all forms) 
per 100 000 population, consisting of Afghanistan, Djibouti, Iraq, Morocco, Somalia, 
Sudan, Yemen and Pakistan, which are among the 22 high burden countries in the 
world. The second category involves countries with an estimated incidence of 25–49 
tuberculosis patients (all forms) per 100 000 population, consisting of Bahrain, 
Egypt, Islamic Republic of Iran, Kuwait, Saudi Arabia and Syrian Arab Republic. 
The last category entails countries with an estimated incidence of 0–24 tuberculosis 
patients (all forms) per 100 000 population consisting of Jordan, Lebanon, Libyan 
Arab Jamahiriya, Oman, Tunisia, United Arab Emirates and Palestine (WHO, 2015). 
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WHO had carried out a multi-country study on diagnosis and treatment delay in 
tuberculosis in seven high and middle burden countries of the EMR (WHO, 2006). In 
addition, out of the 22 countries of the EMR, 9 constitute 94% of the tuberculosis 
cases in the region: Pakistan (43% of tuberculosis cases), Afghanistan (12%), Sudan 
(8%), Iraq (7%), Islamic Republic of Iran (6%), Somalia (6%), Morocco (5%), Egypt 
(4%) and Yemen (3%). The low detection rate of TB in the EMR is mainly 
attributable to the low detection rates of 3% and 9% in Pakistan and Afghanistan in 
2000, respectively (WHO, 2013b).   
Tuberculosis in Yemen is considered a major public health problem, and 
ranks fourth on the priority list of the public health issue (NTCP, 2010a). The cities 
of Taiz and Al Hudaydah in Yemen have the highest TB prevalence(NTCP, 2010a). 
The main centres for the research and diagnosis of most TB patients via sputum 
examination and isolation culture are in these cities (NTCP, 2010a). Taiz city is 
located in the south of Sana'a (about 256 km away). Taiz city has the highest 
incidence of TB in Yemen, with a rate of 12.16%. Al-Hodeida city represents about 
11% of the total population of Yemen and ranks second in the list of TB incidence 
rate (Yemen National Information Center , 2014) (NTCP, 2010a). 
In Yemen, TB patients received standard treatment according to national 
tuberculosis control program (NTCP). The tuberculosis control program (NTCP) 
entails two months of intensive treatment involving the prescribed ingestion of 
ethambutol (E), pyrazinamide (Z), rifampicin (R) and isoniazid (H), followed by at 
least 4 months of isoniazid (H and Rifampicin (R) for both pulmonary (PTB) and 
extrapulmonary (EPTB) tuberculosis. In few cases of EPTB, the program duration 
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extends to 8 months, depending on the patient‟s condition and decision of the 
physician involved (NTCP, 2010a). 
In 2009, in Yemen scenario only 3576 new smear-positive PTB out of 8248 
TB cases were reported at the rate of 15 per 100, 000 population, which indicates 
detection rate of only 60%. The case detection rate was 60%, and the estimated 
prevalent case was only 78 per 100,000 populations with 18720 estimated common 
cases. In 2009, there was approximately 1900 deaths due to TB, which indicates a 
mortality rate of 7.9 per 100,000. 73% of PTB cases fall in the productive age gap 
(15-49 years old), as evident in Table 1.1 (NTCP, 2010a). In 2016, WHO reported a 
notification rate of 3321 smear positives, 2808 smear negatives and 3486 EPTB 
patients (WHO, 2016). The detected TB cases among children was very low with 
fewer than 2 per 100,000, which suggests that TB remains under-detected. This may 
be as a result of several reasons such as difficulties in producing sputum and the 
diagnosis method used by primary health (NTCP, 2010a).  
Table  1.1 Epidemiology of TB 2009 in Yemen 
Descriptions                       
Total population 26 million 
Annual Incidence of smear positive PTB  6,000 (25/100,000 population) 
Total incidence of all form of TB 14,400 (60/100,000 population) 
Prevalence                                                18,720 (78/100,000 population) 
Mortality                                              2000-2500 person (9.9/100,00 Population)                                                                                              
 
1.4 Management and treatment of tuberculosis in Yemen    
In order to manage and increase the success rate of TB cure in Yemen, the 
National Tuberculosis Control Program (NTCP) adopted the directly observed 
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therapy (DOT) strategy, which involves the use of primary health care units to 
delivering health services to tuberculosis patients according to WHO 
recommendations. This comprehensive strategy was developed to prevent the re-
emergence of tuberculosis in Yemen and to effectively treat tuberculosis patients. In 
2015, DOT strategy increased the success rate of TB cure in Yemen to 84%, but still 
under the global success rate (90%) (WHO, 2016).     
To confirm suspected pulmonary tuberculosis, a fast acid tuberculosis 
microscopic examination is performed. The direct smear examination is the main 
diagnostic method for pulmonary TB in Yemen, which is the most reliable method in 
developing countries due to its reliability and cost effectiveness. The subjects can 
also be subjected to direct smear examination that involves the testing of 3 specimens 
of the suspected patient‟s sputum. In addition, all TB patients are subjected to chest 
X-ray for validation. However, the sputum culture is not performed for all TB 
patients. Generally, the diagnosis of extra-pulmonary TB (EPTB) can only be 
performed by a medical officer or specialist, depending on the organ involved. The 
symptoms of TB include swelling with occasional pus drainage when lymph nodes 
are affected; pain and swelling when joints are involved; headache, fever, stiffness of 
the neck and mental disarray in the case of TB meningitis; loss of function in lower 
limbs when there is spinal involvement, and infertility when the genitalia is affected 
(WHO, 2008). 
Based on WHO regulations, Yemen NTCP recommends the use of 4 main 
drugs for the treatment of TB, i.e. rifampicin (R), ethambutol (E), isoniazid (H) and 
pyrazinamide (Z). In 2005, NTCP initiated the use of HRE drugs for an intensive 
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phase of 2 months and HRZE for a continuous phase of 4 months (NTCP, 2010) 
(Table 1.2).  
Table  1.2 Recommended dose, contraindication cases and side effect of TB  drugs 
Drug name Dose 
(mg/kg) 
Maximum 
dose (mg) 
 Contraindicated 
cases 
Side effect 
Isoniazid 5 300 Hepatic 
dysfunction 
-Known 
hypersensitivity 
to rifamycins 
Hepatitis–> stop drug and 
hospitalise Neurotoxicity –
>give pyridoxine Pellagra-like 
syndrome Various skin rashes 
Rifampicin 10 600 -Hepatic 
dysfunction 
-Known 
hypersensitivity 
to rifamycins 
 
Hepatitis –> stop drug and 
hospitalize Respiratory 
syndrome associated with 
collapse and shock –> 
immediate hospitalization 
Purpura, acute haemolytic 
anemia, shock, renal failure – > 
stop drug immediately, never 
given again, mandatory 
hospitalization flushing and/or 
pruritis with or without rash ≥ 
often self-limiting, 
symptomatic treatment flu 
syndrome ≥ symptomatic 
treatment abdominal syndrome 
≥ symptomatic treatment and 
drug 
Pyrazinamide 20-30 
adult 
30-40 
child 
2000 -Hepatic 
dysfunction 
-Known 
hypersensitivity 
to rifamycins 
Hepatitis; joint pain; gout; 
hypersensitivity reactions (rare) 
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Drug name Dose 
(mg/kg) 
Maximum 
dose (mg) 
 Contraindicated 
cases 
Side effect 
Ethambutol 25: adult 
15: child 
1000 Pre-existing optic 
neuritis from any 
cause -Renal 
impairment-
Inability (young 
children <6, 
unconscious 
patients)to report 
visual 
disturbances-
Known 
hypersensitivity 
Visual 
Visual impairment ≥ stop drug  
(NTCP, 2010a) 
1.5 Operational Definitions adapted from NTCP 
The following operational definitions were adopted as per MOH, National 
Tuberculosis Control Program guideline 2009, Table 1.3 
Table  1.3 Operational definitions 
Term Definition 
Cured 
 
A pulmonary TB patient with bacteriologically confirmed TB at 
the beginning of treatment which was smear- or culture-negative 
in the last month of treatment and on at least one previous 
occasion.  
Defaulter 
TB patients consider as default if treatment interrupted for 2 or 
more consecutive months. 
Cohort 
A cohort is a group of patients diagnosed and registered for 
treatment during a specific period (usually one-quarter of a year). 
New TB case 
A patient who has never had treatment for TB or who has taken 
anti-TB drugs for less than 1 month 
Pulmonary 
Positive (PTB) 
Includes patients with at least two sputum specimens that are 
smear positive for acid-fast bacilli (AFB) as determined by 
microscopy analysis; patients with at least one sputum specimen 
that is smear positive for acid-fast bacilli as assessed through 
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Term Definition 
microscopy analysis, with radiographic abnormalities consistent 
with PTB, and whose physician decided to treat with full course 
of chemotherapy; or patients with at least one sputum specimen 
that is smear positive for  AFB as evaluated by microscopy and 
at least one sputum specimen that is culture positive for 
Mycobacterium tuberculosis 
Extra 
Pulmonary 
Tuberculosis 
(EPTB) 
comprises patients with diseases affecting sites other than the 
lung parenchyma, including isolated TB pleural effusion or 
isolated TB intrathoracic lymphadenopathy 
Pulmonary 
Negative 
 
patients whose initial sputum smears are negative (at least three 
specimens tested), who have sputum sent for culture initially, and 
whose subsequent sputum culture result is positive; or patients 
without bacteriological confirmation (also culture negative), with 
radiographic abnormalities consistent with active PTB, without 
response to a course of broad-spectrum antibiotics, and whose 
case is clinically judged to merit treatment by a full course anti-
TB therapy 
Stigma 
Stigma is defined as an undesirable or discrediting attribute that 
an individual possesses, thus reducing the status of that 
individual in the eyes of the society. 
Treatment 
completed 
 
A TB patient who completed treatment without evidence of 
failure BUT with no record to show that sputum smear or culture 
results in the last month of treatment and on at least one previous 
occasion were negative, either because tests were not done or 
because results are unavailable.  
Treatment 
failed 
A TB patient whose sputum smear or culture is positive at month 
5 or later during treatment.  
Died A TB patient who died of any cause during course of treatment  
Transfer out 
 
A patient who has been transferred to another TB register to 
continue treatment  
Treatment 
success 
 
The sum of cured and treatment completed. Moreover, Based 
upon this classification treatment cure and completed is consider 
to be treatment success while other classifications consider being 
unsuccessful treatment (WHO, 2013a)   
Bacteriology 
 
Bacteriology refers to the smear status of pulmonary cases and 
the identification of M. tuberculosis for any case by culture or 
newer methods. (WHO, 2010a) 
Bilateral lungs 
involvement 
It is a pathological state where a lesion appears in both lungs 
High-grade 
sputum 
Grading of sputum is classified based upon number of AFT 
identified during sputum smear microscopy test.  Four types are 
identified (i.e., scantly positive, one positive, two positive and 
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Term Definition 
 three + positive). To shorten and simplify grading types. Scantly 
and one positive recognised as low grade. Moreover, two and 
three positive considered as high grade (Abdurrahman et al., 
2017).  
Khat 
 
Is a shrub plant that grows in East Africa and Yemen. It is a 
natural psych stimulant that has pharmacological effects similar 
to that of amphetamine. (Jaber, Khan, Sulaiman, Ahmad, Anaam, 
et al., 2016) (Kassim, Croucher and Al‟Absi, 2013) 
Literate TB patient can read in the Arabic language.  
New case 
Patients who had never received treatment for TB or who had 
received anti-TB drugs for <1 month. 
Prolong 
duration 
A course of treatment that was >6 months. 
Treatment 
Failure  
A patient who was initially sputum smear-negative and culture- 
positive and remained culture-positive at the end of treatment 
Treatment after 
default  
TB patients were considered return after default, if patient return 
to treatment following interruption of treatment  for 2 or more 
consecutive months and bacteriologically positive.  
prolonged  
sputum 
conversion 
Patients who require longer duration of treatment to obtain a 
bactriological confirmed smear negative  
 
1.6 Problem statement 
1. In Yemen tuberculosis consider as 4th in disease-related causes of death. 
According to the recent WHO global report and the latest National 
Tuberculosis Control Program (NTCP) released in 2010, Yemen is close to 
WHO target of treatment success rate (90%). Despite this success rate, the 
prospective evaluation and risk factors associated with unsuccessful outcome 
during treatment has not been well recorded and assessed.  
2. Several factors associated with treatment such as poverty, monthly income, 
malnutrition and urbanization, in addition to common habits such as chewing 
khat and smoking all continue to aggravate the problem of TB in Yemen. 
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However, these factors have not been evaluated. Assessing these factors can 
play a major role in improving treatment outcome. 
3. Currently, a high human and financial cost is expended on the management 
and diagnosis of tuberculosis, whereas relatively less attention is given to the 
quality of life of TB patients, during and after treatment. The last WHO 
edition of TB management did not place emphasis on HRQoL (WHO, 2016). 
Meanwhile, several of the recent TB studies show a great relationship 
between HRQoL of TB patient and treatment outcome (Kakhki and Masjedi, 
2015; Atif, Sulaiman, et al., 2014; Kastien-Hilka et al., 2016; Chamla, 2004; 
(Rajeswari et al., 2005). Therefore, evaluating HRQoL can play an important 
role in improving quality of life after TB infection, consequently enhancing 
the treatment outcome particularly in countries with low fiscal budget.  
4. The determination of risk factors associated with lengthy treatment course is 
considered crucial because prolonged duration may play a role in Multi-Drug 
Resistance (MDR) (Espinal et al., 2001).  
5. Recent studies have reported increased drug resistance cases in Yemen. 
Yemen remains among the 28 countries that have non-capacity or do not 
partner with laboratories for 2
nd
 line drug susceptibility tests (WHO, 2015). In 
addition, defaulters are considered the main factor that leads to drug 
resistance. Earlier studies have not taken these factors into consideration. 
Therefore, this study hypothesized that determining the associated risk factors 
and reasons for defaulting can play a significant role in optimizing future 
drug resistance and increase success rates.  
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6. Determining the HRQol of defaulters as well as identifying the risk factor 
associated with defaulters HRQoL may play an significant role in optimizing 
future defaulters if considered. 
1.7 Rationale and Importance of overall study  
1. The analysis of clinical outcome is a marker to assess the long-term 
effectiveness of TB progress. 
2. The prospective evaluation of treatment outcome of new tuberculosis (TB) 
patients acts as primary sources of measurement of national tuberculosis 
control program (NTCP) work. It allows the health workers to identify their 
main problems and to take action to improve their performance.  
3. WHO highly recommends the evaluation of the treatment outcome of TB 
patients annually, which should be based on cities, district and national level. 
Also, the assessment of the treatment can give NTP workers the opportunity 
to improve future performance to significantly enhance their success rate.  
4. As a developing country, TB disease remains a significant problem in 
Yemen. TB is ranked 4
th
 on the priority list of diseases that affect public 
health. However, the medical services at the tuberculosis centres 
(consultation, laboratory investigation, X-ray and another service) are not 
made available for free, with the exception of TB medication which is 
supported by government and international organisations (World Health 
Organization, 2012). Approximately 20% of Yemen population live under 
$1.25/day, hence they are considered one of the 20 poorest countries in the 
world (Peck and Pressman, 2013). Various kinds of medical test can be 
provided to the patient such as HIV glucose test to find the co-morbid 
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conditions associated with TB and study the effectiveness of these factors on 
TB patients. 
5. Determination of risk factor associated with prolonging duration may play a 
major role in optimizing future MDR cases, especially in low-income 
countries like Yemen.  
6. There is lack of published studies on treatment outcome as well as HRQoL of 
TB infected persons living in Yemen.  
7. Global reports show higher success rates in most countries, but relatively less 
attention is given to the HRQoL of TB patients in poor countries such as 
Yemen. In addition, various studies have proved there is a relation between 
quality of life of a patient and treatment outcome. 
8. This study contributes to assessing changes in HRQoL during treatment to 
quantify the impact of TB on the quality of life of persons. This research also 
provides vital information that cannot be obtained from conventional clinical 
and functional measurements. 
9. Default in TB treatment can bring about major problems such as drug 
resistance and relapse. Therefore, this study will help identify and evaluate 
the risk factors associated with TB treatment defaulters in order to decrease 
the chances of drug resistance as well as increase the success rate and 
adherence to treatment.   
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1.8 Research contribution  
1. Despite the high success rate of TB treatment in Yemen, the number of TB 
cases particularly in Taiz and Al Hudaydah,cities has increased. Therefore, 
evaluation of the risk factors associated with unsuccessful treatment outcome 
in Taiz and Al Hudaydah can help NTCP to focus more on susceptible 
patients, which may help in increasing the success rate.  
2. This study describes the socio-demographical and clinical aspects of TB 
disease for 12 months and identifies the limitations observed in the diagnosis 
and follow up treatment period.  
3. This study analyzes the HRQoL of TB patients as well as the impact of 
treatment on HRQoL of TB patients. Based on the analysis, the following 
recommendations were made:  
a. Extensive care and support to TB patients in the first two months of 
treatment to improve HRQoL, particularly for MCS, so as to prevent 
patients from defaulting on treatment 
b. Factors such as chewing khat habit, stigmatisation, and duration of 
treatment over 6 months should be considered during TB treatment to 
prevent poor outcome due to the negative role of MCS score.  
c. Thirdly, health workers should focus on increasing the MCS HRQoL in 
Al Hudaydah because of its relatively low educational level.  
4. Taiz and Al Hudaydah have the highest numbers of treatment defaulters in 
Yemen. Therefore, identifying the risk factors associated with defaulters may 
enable NTCP managers to address those factors during TB treatment, which 
can play a role in reducing the numbers of defaulters.  
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5. Evaluating the HRQoL of TB defaulters is essential in identifying future risk 
factors. 
1.9 Aim and objectives  
1.9.1 General Objective 
 To evaluate the treatment outcome, Health related quality of life of 
newly diagnosed tuberculosis patients and factors affecting treatment defaulting in 
Yemen 
1.9.2 Specific Objective  
1. To evaluate the patients socio demographic,  clinical characteristics and risk 
factor associated with unsuccessful treatment outcome of newly diagnosed 
pulmonary tuberculosis patients (PTB). 
2. To identify the risk factors associated with prolong sputum conversion at the 
end of intensive phase, and the prolong treatment duration (a total of 6 
month) of newly diagnosed PTB patients 
3. To evaluate the risk factors associated with treatment defaulting among 
newly diagnosed TB patients.   
4. To evaluate the Health-Related Quality of Life (HRQoL) of newly diagnosed 
Tuberculosis patients and and its associated risk factors. 
5. To assess the Health-Related Quality of Life (HRQoL) among TB defaulters
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2 CHAPTER TWO: LITERATURE REVIEW 
LITERATURE REVIEW 
2.1 Literature Review  
This chapter consists mainly of 6 parts. The first part critically reviews the 
various studies associated with the evaluation of PTB treatment outcome. The second 
part provides an overview and detailed synopsis of several studies associated with 
delay sputum converions. The third part explain the Prolonged Treatment Duration 
(PTD) studies. The fourth part elucidates the evaluation of HRQoL of TB patients. 
The fifth part explains various studies and factors associated with TB defaulters, and 
the sixth part discusses the HRQoL of TB defaulters.  
2.2 Evaluation of treatment outcome of newly diagnosed pulmonary 
tuberculosis (PTB) patients  
The evaluation of TB treatment outcome is valuable, because it monitors the 
treatment progress of TB patients and aids the identification of the risk factors 
associated with treatment success or failure (Mattos et al., 2016). In addition, it can 
be used to assess the overall performance of the tuberculosis control program at the 
local and national levels, which can be useful to predict possible limitations in the 
treatment program and provide new strategies and recommendations for improving 
treatment outcomes (Fernandez, 2014) (WHO, 2010a). The effectiveness of the 
national tuberculosis program is reflected by the proportion of success rate of TB 
patient (Antoine and Che, 2013) (Antoine et al., 2007). Therefore, this study aims to 
predict the risk factors associated with treatment outcome.  
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WHO and several studies recommended the early evaluation of TB patients to 
ensure higher treatment and success rate, particularly in developing countries (WHO, 
2010a); (Vasankari et al., 2007). Nonetheless, most countries have attained the 
success rate 85% posited by WHO, but the risk factors associated with unsuccessful 
treatment outcomes remain understudied. The review of related literature shows that 
no study has fully evaluated and identified the treatment outcome and risk factors 
associated with TB in Yemen. Only a few studies have identified the risk factors 
associated with TB relapse and TB compliance cases in Yemen (Anaam et al., 2013); 
(Anaam et al., 2012). This study focuses only on smear-positive pulmonary 
tuberculosis (PTB) based upon WHO recommendations for analysis of smear-
positive, smear negative and extrapulmonary tuberculosis as a separate program 
(WHO, 2010a).  
Furthermore, WHO reports show that Yemen remains below the revised 
projected target success rate of 90%. (WHO, 2016). Also, TB in Yemen is ranked the 
fourth cause of death and considered a major priority of Yemen ministry of health 
program (NTCP, 2010a). Therefore, prospective evaluation of treatment outcomes in 
Yemen is essential to preventing any future health catastrophe due to TB infection. 
The few studies conducted to evaluate the treatment outcome of TB patients are 
listed below (Table 2.1). 
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Table  2.1 Risk factors associated with unsuccessful treatment outcome 
Study Study Design & Place Sample Size 
Duration & Treatment 
Success Rate (%) 
Risk Factor for Unsuccessful Outcome 
(El-Shabrawy and El-
Shafei, 2016)
 
Retrospective study/Sharkia/ 
Egypt 
480 TB 2013-2014/ 78 Sputum positive on second month, lungs 
cavities, retreatment TB 
(SALEH, 2016) Prospective study / 
Kashmir/India 
72 PTB‴ June 2013-May 2015 / 
88 
Comorbidity such as HIV*, DM
‡
 
(Vasankari et al., 2007)  Retrospective study / Finland 629 PTB‴ 1995-1996 / 70 Male, sex, old age, and previous TB‴ 
treatment 
(Vasankari et al., 2010)  Cohort study  / Finland 276 EPTBº 1995-1996 / 79 Male, older age. 
(Ditah et al., 2008)
 
Prospective study /  Europe 2676  TB″ 2001-2002 Male, old age, PTB‴ and MDR€. 
(Antoine et al., 2007)
 
Retrospective study / England 6652 TB″ 2001-2002 /79 Males, elderly patient, PTB‴, and MDR€ 
(Farah et al., 2005)
 
Register-based cohort study / 
Norway 
655 TB 1996 to 2002 / 79 Older age and Isoniazid resistance 
(Horne et al., 2010) Cohort study / Washington 
state- USA 
3451 TB 1993 to 2005  Older age, male, HIV* comorbidity and 
TB″ treatment by private healthcare 
providers 
 19 
 
Study Study Design & Place Sample Size 
Duration & Treatment 
Success Rate (%) 
Risk Factor for Unsuccessful Outcome 
(Kherad et al., 2009)  Retrospective study / 
Switzerland 
252 TB 1999-2003 / 85 Age, sex, HIV*, Smoking 
(Nguyen et al., 2011) Retrospective study / North 
Carolina 
5311 TB 1993-2003 /  Older age, aggressive TB″ disease, HIV*  
(Singla et al., 2003) Retrospective study / Riyadh 514 PTB‴ 1998-1999 Multiple cavitations, numerous bacilli at 
the time of diagnosis 
(Ukwaja et al., 2016) Retrospective study / Nigeria 1180 TB 2011- 2012 /  
75.7 
TB″ in urban public health, smear 
negative, EPTBº, HIV*, received 
treatment more than 8months 
(Chee et al., 2006) Retrospective study  / Singapore 1646 TB 2001-2002 Chinese ethnicity, younger than 65 years old 
and patient enrolled under DOT
# 
(Mohammed et al., 
2017) 
Retrospective study / Hosanna, 
Ethiopia 
768 TB  2008-2014 /  
43.3 
Age, sex, place of residence, HIV* Type 
of TB 
(Solliman et al., 2012) Retrospective study / Libya 327 TB 2007-2008 /  
58.7 
Libyan nationality 
(Gebrezgabiher et al., 
2016) 
Retrospective study / Ethiopia 1537 TB 2008- 2009 /  
85 
Rural area, PTB‴ and Negative PTB 
(Ade et al., 2014) Retrospective cohort / Benin 383 EPTBº 2011 HIV* 
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Study Study Design & Place Sample Size 
Duration & Treatment 
Success Rate (%) 
Risk Factor for Unsuccessful Outcome 
(Akhtar et al., 2011) A cohort study / Pakistan 582 TB 2003 to 2005 / 66 Family DOT# patients 
(Amo-adjei and 
Awusabo-asare, 2013) 
 
Mixed method approach study 240 TB 1997 to 20010 / 87 Diagnosis methods, stigma. 
(Antoine and Che, 2013) A surveillance report / France 3,787 PTB‴ 2009 Male, born outside France, having the 
previous history of TB 
(Babatunde, 2013) A cross-sectional descriptive 
study  / Nigeria 
78 TB 2010 Smear positive, EPTBº, and HIV* 
patients 
(Belo et al., 2011) Prospective study / Brazil 561 TB 2005 to 2008 Distance to the health centre, BMI
‡
, drug 
resistance and HIV* 
(Berhe, Enquselassie and 
Aseffa, 2012) 
Retrospective study / Ethiopia 427 TB 2009 to 2011 / 89.2 PTB‴, age < 40 years, having family 
member more than 5, unemployment, 
retreatment TB cases. 
(Bøhler, Mustafaa and 
Mørkve, 2005) 
Retrospective study / 
Khartoum -Sudan 
2000 PTB‴ 2000 /  65 History of TB″, Born abroad  
(Fatiregun, Ojo and 
Bamgboye, 2009) 
A longitudinal study design / 
Nigeria 
1245 PTB‴ 2000 / 76.6 Male and Poor knowledge 
(Feng et al., 2011) Prospective observational 
study / China 
992 TB 2007-2009 Older age, the existence of a chronic 
cough, anorexia, and highly fever 
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Study Study Design & Place Sample Size 
Duration & Treatment 
Success Rate (%) 
Risk Factor for Unsuccessful Outcome 
(Getahun et al., 2013) A historical cohort study / 
Addis Ababa 
6451 TB 2005-2009 / 83 Tuberculosis treatment center 
(Glynn et al., 1998) Retrospective study / Malawi 1655 TB 1986-1994  HIV*,  BCG
€
 vaccination 
(Ahmed, Hayat and 
Sciences, 2017) 
A retrospective study/ 
Baluchistan 
219 TB 2014 / 66.4 Retreated TB 
(Harries et al., 1999) Retrospective study / Malawi 8243 PTB″ and 
negative PTB 
1995 / 72 Negative PTB‴, HIV* patients 
(Nahid et al., 2011) Cohort study /   Washington 
state- USA 
3541  TB 1993 to 2005  Age, male gender, co-infection with 
HIV*, taking treatment by privates 
providers 
(Kaur et al., 2008) A longitudinal study in  
Chandigarh / India 
265 TB 2004-2005 /  
90 
Retreatment TB, Age, Sex 
(Firdie, Dejene and 
Tewelde, 2015) 
A cross-sectional study / 
Northern  Ethiopia 
1830 TB 2009 to 2013/ 79.4 Male, Urban residency 
(Khan et al., 2009) Prospective study in  
Peshawar/Pakistan 
306 TB 2007 / 99 Older age, sex 
(Kherosheva et al., 2003) Retrospective study / oblast-
Russia 
749 TB 1999-2000 / 81  HIV* and MDR
€
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Study Study Design & Place Sample Size 
Duration & Treatment 
Success Rate (%) 
Risk Factor for Unsuccessful Outcome 
(Mohandas et al., 2017) Record-based study / Calicut, 
India 
289 TB 2013 / 85 Absence of sputum conversion at second 
month, DM
‡
 
(Lienhardt et al., 1998) Retrospective study / Gambia 1357 PTB‴ 1994-1995 /  
90 
Absence of sputum conversion at 2
nd
 
month, HIV* 
(Manosuthi et al., 2012) 
 
Retrospective study / Thailand 812 TB 2008-2009 /  
52 
HIV* , low body weight, EPTBº and 
older patients 
(Peltzer and Louw, 
2014) 
 Prospective study / South 
Africa 
1196 TB 2014 /70 Leaving in traditional houses, poverty 
and retreatment TB patients 
(Pk et al., 2011) A descriptive study / 
Karnataka, India 
181 TB 2013 / 84 Irregular treatment, alcoholism and HIV* 
(Alemayehu et al., 2017) A cross-sectional study / 
Gondar, Ethiopia 
352 TB 2015  Low income, low education, history of 
TB″ 
(Quy et al., 2003) Prospective study / Vietnam 400 TB 2001/60 No DOT#, Drug cost 
(Raj et al. 2012)  Retrospective study / madhya 
Pradesh- India 
10,964 TB″ 2004 to 2009 / 
 85  
Male, HIV*  
(van Hest et al., 2012) A systematic review / 
European Union 
79 datasets 2000 -2010 Several factors 
(C. S. Wang et al., 2008) Retrospective study / Taiwan 157 PTB‴ 2003-2006  Older age, low BMI €, comorbidity 
conditions 
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Study Study Design & Place Sample Size 
Duration & Treatment 
Success Rate (%) 
Risk Factor for Unsuccessful Outcome 
(Woldeyohannes et al., 
2015)  
Retrospective study / eastern 
Ethiopia 
31,199 TB 2003-2012 /  
85.5 
Male, PTB‴  
(Yen et al., 2012) Retrospective study /  Taipei, 
Taiwan 
1616 TB 2008 / 77.4 Older age, unemployment, tumour, 
MDR
€
 and low education  
(Sunday, 2014) Retrospective study / 
Southwester Nigeria 
965 TB 4 years / 85 HIV*, older age 
(Pawar et al., 2017)  A retrospective comparative 
study / Maharashtra, India 
1915 TB 2015-2016 /   PTB‴ 
(Johnson et al., 2016)  Retrospective cohort study /  
Malaysia 
286 TB 2010-2014  Males, losing weight, smear-positive at 
the end of treatment and smoking 
(Costa, Keny and 
Lawande, 2016)  
Retrospective study / Goa, 
India 
369 TB 2004 -2013 / 
 77 
Not reported 
(Tafess et al., 2016)  Retrospective study/  Ethiopia 34,895 TB 2003 – 2012 /  
97 
Not reported 
 (Liew et al., 2015) Retrospective study /  East 
region,  Malaysia   
21,500 TB 2012 / 78.5 Older age, non-Malaysian, low education, 
no BCG
 
scars, smokers, HIV*, MDR
€
 
and EPTBº  
(Belayneh et al., 2016) Retrospective study / Gondar, 
Ethiopia 
3,800 PTB‴ 2009 -2013 / 79 Not reported 
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Study Study Design & Place Sample Size 
Duration & Treatment 
Success Rate (%) 
Risk Factor for Unsuccessful Outcome 
(Gebreegziabher, Yimer 
and Bjune, 2016) 
Retrospective study / Punjab, 
India 
15,140 TB 2007 – 2012 ,  
90 
Recurrent TB and HIV* 
(Bagga et al., 2017) Prospective study / Ludhiana, 
India 
221 PTB‴ 2010-2011, 82.8 Elderly age, DM‡, smear positive, longer 
distance to centre  
PTB‴: Smear positive Pulmonary Tuberculosis; EPTBº : Extra Pulmonary Tuberculosis; HIV*: Human Immunodeficiency Virus;  BCG€ : Bacille Calmette-
Guerin; MDR€: Multi Drug Resistance DOT#, DM‡: Diabetic Mellitus  
